Wedbush Upgrades Karyopharm Therapeutics (KPTI) to Outperform
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $1.82 --0%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Wedbush analyst David Nierengarten upgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Neutral to Outperform with a price target of $19.00.
For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.
Shares of Karyopharm Therapeutics closed at $11.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
- KeyBanc Upgrades Innovage Holding Corp (INNV) to Overweight
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
